Cargando…

Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor

SIMPLE SUMMARY: In this study, we apply the ERBB2-chimeric antigen receptor (CAR)-modified natural killer (NK) cell line NK-92 (NK-92/5.28.z), a well-defined, good manufacturing practice (GMP)-compliant, third-party, off-the-shelf immune effector cell product as a novel immunotherapeutic approach fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gossel, Leonie D. H., Heim, Catrin, Pfeffermann, Lisa-Marie, Moser, Laura M., Bönig, Halvard B., Klingebiel, Thomas E., Bader, Peter, Wels, Winfried S., Merker, Michael, Rettinger, Eva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004684/ https://www.ncbi.nlm.nih.gov/pubmed/33809981 http://dx.doi.org/10.3390/cancers13061443

Ejemplares similares

ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma
por: Merker, Michael, et al.
Publicado: (2020)

ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma
por: Heim, Catrin, et al.
Publicado: (2023)

Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children
por: Merker, Michael, et al.
Publicado: (2017)

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity
por: Boissel, Laurent, et al.
Publicado: (2013)

Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models
por: Rettinger, Eva, et al.
Publicado: (2012)

Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells
por: Bremm, Melanie, et al.
Publicado: (2019)

In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy
por: Bremm, Melanie, et al.
Publicado: (2016)

Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia
por: Jarisch, Andrea, et al.
Publicado: (2022)

Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting
por: Sutherland, Ashley R., et al.
Publicado: (2020)

Directed Differentiation of Mobilized Hematopoietic Stem and Progenitor Cells into Functional NK Cells with Enhanced Antitumor Activity
por: Oberoi, Pranav, et al.
Publicado: (2020)

Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity
por: Zhang, Congcong, et al.
Publicado: (2017)

Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB.
por: Aasland, R., et al.
Publicado: (1988)

A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against Rhabdomyosarcoma
por: Wagner, Juliane, et al.
Publicado: (2017)

Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers
por: Pfeifer Serrahima, Jordi, et al.
Publicado: (2023)

In vitro migration and proliferation (“wound healing”) potential of mesenchymal stromal cells generated from human CD271(+) bone marrow mononuclear cells
por: Latifi-Pupovci, Hatixhe, et al.
Publicado: (2015)

Haploinsufficiency of the lysosomal sialidase NEU1 results in a model of pleomorphic rhabdomyosarcoma in mice
por: Machado, Eda R., et al.
Publicado: (2022)

ErbB2/HER2/Neu resembles an autoinhibited invertebrate EGF receptor
por: Alvarado, Diego, et al.
Publicado: (2009)

cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma
por: Semiz, Huseyin Salih, et al.
Publicado: (2023)

A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR
por: Arndt, Claudia, et al.
Publicado: (2019)

Retargeting of Viruses to Generate Oncolytic Agents
por: Verheije, M. H., et al.
Publicado: (2012)

Retargeting the management of hypercholesterolemia – focus on evolocumab
por: Colletti, Alessandro, et al.
Publicado: (2016)

Endothelial Retargeting of AAV9 In Vivo
por: Bozoglu, Tarik, et al.
Publicado: (2022)

Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis
por: Sasso, Emanuele, et al.
Publicado: (2020)

ErbB2/Her2-specific NK cells for adoptive immunotherapy of glioblastoma
por: Zhang, Congcong, et al.
Publicado: (2014)

HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma
por: Plum, Patrick Sven, et al.
Publicado: (2019)

Retargeting Strategies for Oncolytic Herpes Simplex Viruses
por: Campadelli-Fiume, Gabriella, et al.
Publicado: (2016)

Retargeted adenoviruses for radiation-guided gene delivery
por: Kaliberov, S A, et al.
Publicado: (2016)

Tools for retargeting proteins within Aspergillus nidulans
por: Suresh, Subbulakshmi, et al.
Publicado: (2017)

The transcription factor TAL1 and miR-17-92 create a regulatory loop in hematopoiesis
por: Meyer, Annekarin, et al.
Publicado: (2020)

Adoptive cellular immunotherapy for refractory childhood cancers: a single center experience
por: Merker, Michael, et al.
Publicado: (2019)

Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice
por: Ianzano, Marianna L., et al.
Publicado: (2013)

Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”
por: Feldmann, Anja, et al.
Publicado: (2017)

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
por: Romanski, Annette, et al.
Publicado: (2016)

Retargeting Adenoviral Vectors to Improve Gene Transfer into Tumors
por: Hogg, Richard T., et al.
Publicado: (2010)

A VHH-Based Anti-MUC1 Chimeric Antigen Receptor for Specific Retargeting of Human Primary T Cells to MUC1-Positive Cancer Cells
por: Rajabzadeh, Alireza, et al.
Publicado: (2021)

Validation of an ICH Q2 Compliant Flow Cytometry-Based Assay for the Assessment of the Inhibitory Potential of Mesenchymal Stromal Cells on T Cell Proliferation
por: Piede, Natascha, et al.
Publicado: (2023)

Evaluation of C-ErbB-2 Overexpression and Her-2/neu Gene Copy Number Heterogeneity in Barrett’s Adenocarcinoma
por: Walch, Axel, et al.
Publicado: (2000)

Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer
por: Schroeder, Richard L., et al.
Publicado: (2014)

ErbB2/HER2-specific NK cells for adoptive cancer immunotherapy
por: Zhang, Congcong, et al.
Publicado: (2013)

Image content retargeting: maintaining color, tone, and spatial consistency
por: Artusi, Alessandro, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pnv9n2l98tlpo29t4lfr7h0432